If you have questions, please contact us.
Our Clinical Trials
Vor Bio is currently conducting two clinical trials for AML and MDS.
VBP101 Clinical Trial
The VBP101 trial, a Phase 1/2a study of trem-cel in combination with Mylotarg™, is actively enrolling patients. This clinical trial will evaluate trem-cel in patients with AML or MDS undergoing an allogeneic hematopoietic cell transplant (HCT).
VBP301 Clinical Trial
The VBP301 trial studying VCAR33ALLO, a donor-derived CD33-directed CAR-T cell therapy, is actively enrolling patients. VCAR33ALLO is being studied in the VBP301 clinical trial, which focuses on patients who have relapsed following allogeneic stem cell transplant, including patients who have previously received trem‑cel.
The science behind the Vor Bio platform
We are applying proven technologies in new ways by shielding healthy donor HSCs for protection and enabling use of modalities such as ADCs and CAR-Ts post-transplant.